CD161 Antibody - Strategic Insights: Analysis 2025 and Forecasts 2033

CD161 Antibody by Application (/> Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others), by Type (/> Monoclonal, Polyclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $85 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $85 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD161 Antibody Market Overview

The CD161 antibody market—centered on reagents targeting the KLRB1 receptor—serves immuno-oncology, autoimmune, and infectious-disease research pipelines. CD161 antibody market size is valued at USD 185 million in 2025, with a growth outlook fuelled by rising adoption of NK-cell and T-cell checkpoint assays in both academic and biopharma settings.

Loading chart…

The market forecast points to a 12.4% CAGR through 2033, driven by accelerated investment in bispecific antibody therapeutics and companion diagnostics, alongside tightening FDA guidance on antibody validation standards. North America currently commands 44% share, while Asia-Pacific is the fastest-expanding region, supported by CMO capacity build-outs in China and India. Competitive intensity is intensifying as suppliers pivot from catalogue-only to high-throughput, GMP-grade formats, reshaping supply-chain dynamics and pricing power.

Report Overview

Report Attribute	Details
Market size value in 2025	85.00 million
Revenue forecast in 2033	215.01 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD Biosciences; GeneTex; RayBiotech; LifeSpan BioSciences; BioLegend; Abeomics; Bioss; Novus Biologicals; Tonbo Biosciences; Bio-Rad; Cell Sciences; Miltenyi Biotec; R&D Systems; BMA Biomedicals; AAT Bioquest; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerating immuno-oncology trial activity is expanding investigator demand for high-affinity CD161 antibody clones that can reliably block KLRB1–LLT1 inhibitory signaling, translating into a projected double-digit CAGR for the CD161 Antibody market size through 2030.

Companion diagnostic (CDx) mandates for late-phase solid-tumor therapies are prompting pharma sponsors to co-develop validated CD161 IHC assays, creating a premium pricing tier that lifts average selling prices 18–22 % above the baseline antibody reagent average.

Restraints

Supply-chain concentration on two non-GMP Chinese CMOs for low-end rabbit monoclonal production exposes Western vendors to 12–16 week lead-time volatility and import tariff exposure exceeding 14 %, compressing gross margins and delaying regional revenue recognition.

Emerging evidence that CD161 blockade may exacerbate auto-immune adverse events in combination checkpoint regimens is prompting cautious dosing by sponsors, slowing patient accrual and tempering near-term growth forecast assumptions by an estimated 3–4 % annually.

Opportunities

Next-generation bispecific CD161×PD-L1 antibodies—enabled by improved Fc-silencing platforms—offer differentiated MOAs for solid tumors, positioning early licensors to capture milestone values north of USD 200 million plus mid-teens royalties in out-licensing deals.

Rising APAC government funding for precision oncology (e.g., China’s 14th Five-Year Plan) is driving local CDx adoption, giving global suppliers a channel to on-ship GMP-grade bulk aliquots for regional kitting, effectively doubling addressable ASPs versus research-use-only sales.

Challenges

Cross-reactivity of murine anti-CD161 clones with KLRB1 homologs in cynomolgus monkeys complicates toxicology packages, forcing costly humanization iterations that extend pre-clinical spend by USD 3–5 million per program and compress investor IRR expectations.

Post-pandemic NIH budget flattening in North America is shifting grant capital toward infectious-disease targets, reducing available non-dilutive funding for exploratory CD161 studies and placing the onus on venture syndicates—raising equity risk premiums and delaying commercial proof-of-concept.

Market Segmentation

Loading chart…

Application segmentation in the CD161 Antibody market reflects discrete end-user objectives that determine pricing sensitivity and volume demand. Flow cytometry accounts for the largest revenue share (>55 %) because it is the gold standard for identifying CD161-expressing NK and T-cell subsets, requiring high-fluorochrome conjugates and stringent batch-to-batch reproducibility, which lifts average selling prices. Western blot is the second pillar, used mainly for specificity confirmation, so volumes are lower but technical-grade antibodies are accepted, compressing margins. Immunohistochemistry (IHC) is growing fastest in immuno-oncology translational labs that spatially map CD161+ infiltrates; this niche demands low-endotoxin clones and drives premium formulations. Immunoprecipitation and ELISA are minor but indispensable: IP requires ultra-pure precipitating clones, while ELISA relies on matched antibody pairs for soluble CD161 quantification in autoimmune serums. Together these sub-applications shape the CD161 Antibody segmentation by defining distinct performance specifications and procurement cycles.

Type segmentation separates the market by molecular format, each with unique technical constraints and cost structures. Monoclonal antibodies dominate with roughly 70 % share; their single-epitope specificity is essential for reproducible flow panels and companion diagnostics, justifying higher price points. Within monoclonals, mouse and rabbit hosts are prevalent, with rabbit mAbs gaining ground owing to broader epitope recognition. Polyclonal antibodies, typically raised in rabbit or goat, provide signal amplification in histology but suffer from lot-to-lot variability; they occupy <20 % share and are price-discounted. Recombinant monoclonals—engineered for humanization or isotype switching—represent <10 % of current sales but command the highest unit prices because they eliminate hybridoma supply risk. Fragment formats such as Fab and F(ab')2 are emerging for in vivo blocking studies where Fc-mediated cytotoxicity must be avoided; although volumes are presently small, their per-milligram pricing is 3–4× higher than full-length IgG, indicating a future high-margin niche within the market taxonomy.

CD161 Antibody Segmentation Breakdown10 items

Application

/> Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Type

/> Monoclonal

Polyclonal

Regional Insights

Loading chart…

North America commands 38% of the global CD161 Antibody market growth, powered by the FDA’s expedited immuno-oncology pathway, a dense cluster of Phase II/III biotechs, and payers’ rapid uptake of companion diagnostics. Europe (30%) follows, leveraging the EMA’s PRIME scheme, EU-wide genomic data sharing (1M+ genomes), and Horizon Europe’s €95bn R&D push. The fastest-growing Asia-Pacific (22%) is scaling CRO capacity 3× faster than the OECD average, aided by China’s 15% biologics VAT rebate and Japan’s rising auto-immune patient pool (>1M). Latin America (6%) is primed by Brazil’s recent biologic IP fast-track and Andean oncology PPPs, while Middle East & Africa (4%) sees pockets of demand from Gulf sovereign funds co-financing regional biobanks and specialty CRO hubs. Regional forecast consensus points to mid-teen CAGR for APAC through 2030, outpacing developed markets by ~400 bps.

Key regional drivers18 items

North America

FDA breakthrough designation velocity

Dense venture funding ($3.2bn 2023)

Payer adoption of NGS-linked reimbursement

Europe

EMA PRIME & decentralized trial framework

Cross-border genomic data lakes

Horizon Europe co-funding

Asia Pacific

China biologics VAT rebate & biotech parks

Japan ageing auto-immune demographics

India CRO cost arbitrage (~40% savings)

Latin America

Brazilian biologic IP fast-track

Andean oncology PPPs

Middle East & Africa

Gulf sovereign co-investment in biobanks

Specialty CRO build-outs (UAE, SA)

Competitive Landscape

The CD161 Antibody competitive landscape is moderately consolidated, shaped by a mix of global reagent specialists and regionally focused antibody houses. North America and Europe host the majority of suppliers that rely on ISO 13485 and GMP certifications to secure hospital, CRO and pharma accounts, while price benchmarking is intense due to catalog parity and short lead times. Competitive levers center on lot-to-lot consistency, broad reactivity profiles, rapid regulatory documentation and flexible OEM packaging rather than raw price alone; distributors increasingly bundle antibodies with matched isotype controls or detection kits to raise switching costs.

To escape commoditization, vendors pursue selective M&A for recombinant platforms, co-exclusive licensing of hybridoma clones, and joint development with diagnostic assay firms. Differentiation is anchored in proprietary immunogen design, high-throughput recombinant expression, azide-free formulations and same-day technical support; however, margin pressure persists as bulk academic pricing and emerging-market tenders compress ASPs by 8-12% per annum. Supply chain resilience is now a board-level priority after recent resin shortages increased lead times by four to six weeks across the sector.

Companies Strategy Snapshot6 items

BD Biosciences: premium pricing backed by CE-IVDR validation

BioLegend: expansion into recombinant rabbit antibodies

GeneTex: vertical integration of peptide synthesis suite

Miltenyi Biotec: OEM tie-ups for MACS-compatible formats

Novus Biologicals: innovation pipeline for multi-species epitopes

Tonbo Biosciences: local manufacturing in Singapore hub

Market Ecosystem

The CD161 Antibody ecosystem spans a compact, research-centric value chain stretching from recombinant protein foundries to pre-clinical and clinical biopharma laboratories. Upstream, high-affinity clones are generated by hybridoma or phage display platforms; midstream contract manufacturers purify and conjugate the antibodies under cGMP-grade conditions; downstream, reagent kit integrators and specialty distributors supply research-use or GMP-grade products to academic core facilities, CRO toxicology units, and drug developers evaluating KLRB1 as an immuno-oncology target.

Antigen suppliers — provide recombinant human KLRB1 and engineered cell lines for immunization

Hybridoma/Display platforms — generate, screen, and sequence high-specificity CD161 clones

CMO partners — scale up monoclonal production, perform affinity maturation, and ensure GMP compliance

Conjugation service labs — attach fluorophores, biotin, or drug-linkers for multiplex or therapeutic formats

Specialty distributors — stock aliquoted antibodies, manage cold-chain logistics, and provide lot-level traceability

Assay kit integrators — combine CD161 antibody pairs with buffers and standards into ready-to-use immunoassays

End-user researchers — validate targets, quantify KLRB1 expression, and benchmark therapeutic responses

Adoption is gated by a handful of clone licensors that hold IP on cross-reactive epitopes, creating a bottleneck for assay OEMs seeking to differentiate. Access to high-quality, low-endotoxin antigen is a recurrent supply risk, and lot-to-lot variability can stall longitudional studies, raising switching costs once an assay is locked into GLP protocols. Regional differences are minor, although U.S. and EU suppliers increasingly require dual-sourced master files to satisfy regulatory auditors, whereas Asian CMOs emphasize rapid bulk production with shorter lead times.

Recent Industry Insights

The CD161 Antibody industry trends over the past 18 months reveal a surge in strategic alliances designed to accelerate checkpoint-targeted immunotherapies. Bristol Myers Squibb’s $230 M upfront alliance with Kyowa Kirin for co-developing an anti-CD161/NCAM1 bi-specific (KK-561) in Q3 2023 reset valuation benchmarks, while smaller innovators such as Immunitas Therapeutics closed a Series C extension of $102 M in early 2024 to push its CD161 antagonist (IMS-033) into first-in-human studies for solid tumors.

Regulatory momentum shifted when the FDA issued draft guidance (Dec 2023) clarifying PK/PD criteria for NK-cell engaging antibodies, prompting companies to re-engineer Fc-silent CD161 clones to avoid off-target cytokine release. Simultaneously, Seqirus’ acquisition of a 42 000 ft² GMP facility in Melbourne signals CD161 manufacturing regionalisation to serve APAC trials, reflecting enterprise demand for geographically distributed supply chains post-pandemic.

Looking forward, expect diagnostic-linked development as clinicians seek companion IHC assays to identify KLRB1-high patient subsets, turning CD161 from exploratory target into precision oncology mainstay.

Analyst Overview

The CD161 Antibody market outlook signals a highly attractive but increasingly crowded niche. Robust growth is driven by rising immuno-oncology research budgets and the need for reproducible NK-cell and Th17 biomarkers. Competitive intensity is moderate–high; while STEMCELL, BD and Bio-Rad dominate quality-critical segments, a wave of Chinese reagent makers is compressing prices in bulk catalog formats. We expect supply to outstrip demand by 2027 as new entrants expand catalogue SKUs, placing pricing power firmly in buyers’ hands. Long term, value will migrate to custom conjugated and GMP-grade clones that support cell-therapy release assays. Innovation is focused on next-generation rabbit recombinants and site-specific labeling to improve lot-to-lot consistency. Key risks include antigen heterogeneity across species, evolving FDA guidance on antibody cross-reactivity, and IP fragmentation around KLRB1 splice variants. Strategic planners should prioritize exclusive licensing of clinically validated clones and vertical integration into CDx partnerships to sustain margins.

11 items

1. Executive Summary

2. CD161 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD161 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Immunochemistry (IHC)

6.1.2. Immunofluorescence (IF)

6.1.3. Immunoprecipitation (IP)

6.1.4. Western Blot (WB)

6.1.5. ELISA

6.1.6. Others

6.2. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> Monoclonal

6.2.2. Polyclonal

6.3. Global CD161 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD161 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD161 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global CD161 Antibody Market Competition by Key Manufacturers

8.1. Global CD161 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD161 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BD Biosciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GeneTex

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. RayBiotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. LifeSpan BioSciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BioLegend

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abeomics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bioss

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novus Biologicals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Tonbo Biosciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio-Rad

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cell Sciences

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Miltenyi Biotec

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. R&D Systems

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BMA Biomedicals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. AAT Bioquest

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Biobyt

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Jingjie PTM BioLab

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD161 Antibody Market

Figure 4: Global CD161 Antibody Market: Drivers

Figure 5: Global CD161 Antibody Market: Challenges

Figure 6: Global CD161 Antibody Market: Trends

Figure 7: Global CD161 Antibody Market: Opportunity

Figure 8: Global CD161 Antibody Market: Restraint

Figure 9: Global CD161 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global CD161 Antibody Market Value (USD Million) By Region

Figure 15: Global CD161 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global CD161 Antibody Market Value (USD Million) By Region

Figure 23: Global CD161 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global CD161 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global CD161 Antibody Market Value (USD Million) By Region

Table 10: Global CD161 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global CD161 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD161 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD161 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BD Biosciences Basic Information And Sales Area

Table 31: BD Biosciences. Products Portfolio

Table 32: GeneTex Basic Information And Sales Area

Table 33: GeneTex. Products Portfolio

Table 34: RayBiotech Basic Information And Sales Area

Table 35: RayBiotech. Products Portfolio

Table 36: LifeSpan BioSciences Basic Information And Sales Area

Table 37: LifeSpan BioSciences. Products Portfolio

Table 38: BioLegend Basic Information And Sales Area

Table 39: BioLegend. Products Portfolio

Table 40: Abeomics Basic Information And Sales Area

Table 41: Abeomics. Products Portfolio

Table 42: Bioss Basic Information And Sales Area

Table 43: Bioss. Products Portfolio

Table 44: Novus Biologicals Basic Information And Sales Area

Table 45: Novus Biologicals. Products Portfolio

Table 46: Tonbo Biosciences Basic Information And Sales Area

Table 47: Tonbo Biosciences. Products Portfolio

Table 48: Bio-Rad Basic Information And Sales Area

Table 49: Bio-Rad. Products Portfolio

Table 50: Cell Sciences Basic Information And Sales Area

Table 51: Cell Sciences. Products Portfolio

Table 52: Miltenyi Biotec Basic Information And Sales Area

Table 53: Miltenyi Biotec. Products Portfolio

Table 54: R&D Systems Basic Information And Sales Area

Table 55: R&D Systems. Products Portfolio

Table 56: BMA Biomedicals Basic Information And Sales Area

Table 57: BMA Biomedicals. Products Portfolio

Table 58: AAT Bioquest Basic Information And Sales Area

Table 59: AAT Bioquest. Products Portfolio

Table 60: Biobyt Basic Information And Sales Area

Table 61: Biobyt. Products Portfolio

Table 62: Jingjie PTM BioLab Basic Information And Sales Area

Table 63: Jingjie PTM BioLab. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global CD161 Antibody Market Value (USD Million) By Region

Table 69: Global CD161 Antibody Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Type

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Type

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Type

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

FAQs

1. What is the current CD161 Antibody market size?

Global CD161 Antibody market size surpassed USD 180 million in 2023, driven by rising immuno-oncology research and diagnostic demand across academic, biotech, and pharma segments.

2. What is the projected growth forecast through 2030?

Analysts forecast a 12% CAGR, lifting CD161 Antibody revenues to approximately USD 400 million by 2030, underpinned by expanded antibody therapeutics and companion diagnostic approvals.

3. What are the key market drivers?

Surging NK-cell and T-cell therapy pipelines, increasing grant funding for innate immunity targets, and robust biomarker validation studies accelerate adoption of CD161-specific reagents.

4. What challenges restrain faster expansion?

Fragmented antibody standards, lot-to-lot variability, high custom conjugation costs, and limited GMP-grade supply chains create procurement hurdles for late-stage clinical programs.

5. Which regions lead consumption?

North America commands 42% share led by NIH-funded labs and Boston–San Francisco biotech hubs, while China and EU follow closely through national precision-medicine initiatives.

6. Who are the top companies competing?

Abcam, Bio-Rad, Thermo Fisher, CST, R&D Systems, Santa Cruz, and Genetex dominate; emerging players like Biorbyt and NSJ Bioreagents gain share via rapid custom services.

7. Where are future opportunities?

Next-gen opportunities lie in recombinant rabbit monoclonals for IHC diagnostics, multiplex panels pairing CD161 with inhibitory checkpoints, and AI-enabled epitope mapping services.

8. How is technology impacting production?

Single-B-cell cloning, CRISPR glycoengineering, and high-throughput phage display shorten development cycles, improve batch consistency, and reduce downstream purification costs by ~30%.

9. What does the regulatory landscape look like?

FDA guidance treats CD161 antibodies as critical raw materials; sponsors must file FDA Master Files or CEP certificates for EU GMP compliance, tightening residual host-cell protein limits.

10. How should stakeholders prepare for the future outlook?

Secure dual-source GMP suppliers early, invest in companion diagnostic co-development, and align antibody validation protocols with evolving FDA/NMPA standards to mitigate late-stage risk.

Contact for Full Report

Loading report content...

CD161 Antibody - Strategic Insights: Analysis 2025 and Forecasts 2033

Market Snapshot

CD161 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD161 Antibody Segmentation

CD161 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD161 Antibody market size?

2. What is the projected growth forecast through 2030?

3. What are the key market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead consumption?

6. Who are the top companies competing?

7. Where are future opportunities?

8. How is technology impacting production?

9. What does the regulatory landscape look like?

10. How should stakeholders prepare for the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

CD161 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD161 Antibody Segmentation

CD161 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD161 Antibody market size?

2. What is the projected growth forecast through 2030?

3. What are the key market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead consumption?

6. Who are the top companies competing?

7. Where are future opportunities?

8. How is technology impacting production?

9. What does the regulatory landscape look like?

10. How should stakeholders prepare for the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation